LAVA-051
Our lead program, LAVA-051, is a unique, humanized gamma delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. Unique to LAVA-051, it activates both Vγ9Vδ2 Vgamma9 Vdelta2 T cells as well as invariant natural killer T-cells, which represent another conserved immune effector cell population, in a target dependent manner.
Enrollment is underway in our open-label, multi-center, Phase 1/2a clinical trial of LAVA-051 for the treatment of relapsed and/or refractory CLL, MM and AML. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-051. Click here to learn more about the trial.
LAVA-1207
LAVA-1207 is a Gammabody® that conditionally activates Vγ9Vδ2 (Vgamma9 Vdelta2) T cells upon crosslinking to prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells, including metastatic castration-resistant prostate cancer (mCRPC). We have achieved preclinical proof-of-concept with LAVA-1207 by demonstrating efficacy and safety in a variety of preclinical models.
Enrollment is underway in our open-label, multi-center, Phase 1/2a clinical trial of LAVA-1207 for the treatment of mCRPC. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-1207.
Early-Stage Pipeline
In addition to our two named lead programs, we are advancing a portfolio of early-stage programs.
Janssen Collaboration
In May 2020, we entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of this agreement, we will discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. We received an upfront payment, and are eligible to receive potential development and commercial milestones, and future tiered royalties.